We have reported that GLP-1R expression is enhanced by inhibition of GLP-1 degradation via dipeptidyl peptidase-4 (DPP-4) inhibition, and that GLP-1R activity is decreased in chronic kidney disease (CKD) [15]. Here, DPP4 is linked to chronic kidney disease.